Leukemia, Myeloid, Acute: all 3,035 studies
Page 15 of 31. Open to participants first (746), then studies with results posted, then the rest; newest registration first within each.
- Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593Not applicableResults posted
- Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00105001Phase 2Results posted
- Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid LeukemiaCompletedNCT00096122Phase 1/2Results posted
- Tipifarnib in Treating Patients With Acute Myeloid Leukemia in RemissionCompletedNCT00093470Phase 3Results posted
- Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic CancerCompletedNCT00089011Phase 2Results posted
- Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).CompletedNCT00088218Phase 2Results posted
- AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)CompletedNCT00071006Phase 2Results posted
- Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete RemissionCompletedNCT00070135Phase 2Results posted
- Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)CompletedNCT00067028Phase 2Results posted
- Randomized Double Cord Blood Transplant StudyCompletedNCT00067002Phase 2Results posted
- S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid LeukemiaTerminatedNCT00053014Phase 2Results posted
- Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancerCompletedNCT00049504Phase 2Results posted
- Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory AnemiaCompletedNCT00046930Phase 3Results posted
- PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)CompletedNCT00045942Phase 1/2Results posted
- Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in RemissionCompletedNCT00045435Phase 2Results posted
- Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological MalignanciesCompletedNCT00040846Phase 2Results posted
- Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00003875Phase 2Results posted
- Specialized Blood Cell Transplants for Cancers of the Blood and Bone MarrowCompletedNCT00003838Phase 2Results posted
- Murottal as Adjunctive Intervention in PediatricCompletedNCT07861477Not applicable
- Chidamide in HR-AMLActive, not recruitingNCT07822789
- A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCTActive, not recruitingNCT07779031Phase 1/2
- Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive ChemotherapyCompletedNCT07773909Phase 4
- Fitness in Elderly AML PatientsActive, not recruitingNCT07598838
- Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 MutationWithdrawnNCT07566585Phase 1
- A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute LeukemiaWithdrawnNCT07498465Phase 1
- Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid LeukemiaCompletedNCT07458542
- Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AMLActive, not recruitingNCT07437170Phase 2
- Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid LeukemiaActive, not recruitingNCT07411586Phase 1
- Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the OutcomeCompletedNCT07379528
- Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AMLWithdrawnNCT07338357Early Phase 1
- A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute LeukemiaCompletedNCT07295951Phase 1
- Combination of HMA and Venetoclax With Posaconazole in Patients With Acute Myeloid Leukemia: A Study of Plasma ConcentrationsCompletedNCT07254611
- Clinical Study of Selinexor-Based Chemotherapy With Minimal or No Cytotoxic Agents in Treatment-Naïve AML Patients Unsuitable for Intensive Therapy: Focusing on Rapid Reduction of Blast CellsCompletedNCT07236931Not applicable
- Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid LeukemiaActive, not recruitingNCT07232953Phase 2
- AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only AssessmentCompletedNCT07203885Not applicable
- Allogeneic HCT Using Conditioning Regimen of BuFluATG for AML CR1CompletedNCT07155382
- Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After TransplantationActive, not recruitingNCT07094464Phase 1
- ENLIGHT-AML - An Open-label, Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaWithdrawnNCT07084584Phase 1
- Feasibility and Safety of Home Blood Count Measurement and Transfusions in Patients With Acute Myeloid LeukemiaCompletedNCT07062250Not applicable
- Use of Venetoclax , AML , Sohag , EgyptCompletedNCT06993883
- Biomarkers in Patients With Anemia-Induced Thrombocytopenic BleedingActive, not recruitingNCT06947044Not applicable
- The Role and Mechanism of TCR-T Cells in Immunotherapy for Acute Myeloid LeukemiaCompletedNCT06904859Early Phase 1
- A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid LeukemiaWithdrawnNCT06903702Phase 2
- Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell TransplantationCompletedNCT06865352Phase 1/2
- Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid LeukemiaSuspendedNCT06802523Phase 1
- GITMO AML/MDS-Relapse Registry StudyCompletedNCT06790680
- Expectations of Patients in Palliative SituationActive, not recruitingNCT06786897
- Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive ChemotherapyWithdrawnNCT06770257Phase 2
- CART123 + Ruxolitinib in Relapsed/Refractory AMLActive, not recruitingNCT06768476Phase 1
- CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I TrialActive, not recruitingNCT06765876Early Phase 1
- Liquid Micro-biopsy: a Novel Approach to Study Tumor Microenvironment From the Peripheral BloodActive, not recruitingNCT06764589
- Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell TransplantCompletedNCT06734585
- Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1TerminatedNCT06714591Phase 1
- Assessing Refractoriness and Infectious Survival Events in AMLCompletedNCT06709235
- A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid LeukemiaSuspendedNCT06709131Phase 1
- BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDSTerminatedNCT06704152Phase 1/2
- ABBA CORD: dCBT w/ Abatacept for aGVHD ProphylaxisSuspendedNCT06680661Phase 2
- Venetoclax + Azacitidine in Patients With Acute Myeloid LeukemiaActive, not recruitingNCT06668558Phase 2
- The Risk of Acute Myeloid Leukaemia in Patients With Ewing's SarcomaCompletedNCT06659224
- A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic NeoplasmsActive, not recruitingNCT06651229Phase 1
- Association of Ex Vivo Drug Response ( EVDR) and Clinical Outcome in Acute Myeloid Leukaemia (EXCYTE-2)CompletedNCT06648512
- 2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AMLSuspendedNCT06626633Phase 1
- A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic NeoplasmsActive, not recruitingNCT06618001Phase 1
- Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AMLActive, not recruitingNCT06578247Phase 3
- Extension Study, Pilot, Compassionate Use of Azacitidine 300 mg Film Coated Tablets for Acute Myeloid Leukaemia (AML) PatientsActive, not recruitingNCT06572982Not applicable
- Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched DonorWithdrawnNCT06572631Phase 1
- Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in FranceCompletedNCT06565975
- A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMMLTerminatedNCT06563804Phase 1/2
- Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT06541444Early Phase 1
- Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT06541405Early Phase 1
- Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AMLSuspendedNCT06514261Phase 1
- Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNCT06497062Phase 2
- DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM TrialSuspendedNCT06492707Phase 1
- A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic MalignanciesCompletedNCT06492304Phase 1/2
- FLT3 Clonal Evolution in Patients With Acute Myeloid LeukemiaCompletedNCT06463639
- A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive ChemotherapyActive, not recruitingNCT06456463Phase 2
- Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid LeukemiaSuspendedNCT06454409Phase 1
- Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense ChemotherapyTerminatedNCT06449482Phase 1/2
- Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT06445907Phase 1
- Expanded Access to ABBV-787No longer availableNCT06439966
- Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/RefractoryCompletedNCT06429670
- Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AMLActive, not recruitingNCT06429098Phase 2
- Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeTerminatedNCT06419634Phase 1
- Retun-to-school Adaptation Program for Children With CancerCompletedNCT06389357Not applicable
- A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive TherapyActive, not recruitingNCT06384261Phase 2
- Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) PatientsActive, not recruitingNCT06379360Phase 2
- CD155 Expression in Acute Myeloid LeukemiaCompletedNCT06369662
- A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart ReviewWithdrawnNCT06362031
- Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.Active, not recruitingNCT06359002Phase 1
- DEC-C and Thioguanine for R/R AMLWithdrawnNCT06351306Phase 2
- Oral Azacitidine Maintenance Post-CPX 351CompletedNCT06349239
- Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell TransplantWithdrawnNCT06337331Phase 2
- Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML)CompletedNCT06326697Phase 1
- SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDSActive, not recruitingNCT06325748Phase 1
- Refining the Role of Mid-induction Bone Marrow Biopsy in Acute Myeloid Leukemia: A Pilot StudyActive, not recruitingNCT06323590
- Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AMLTerminatedNCT06268574Phase 2
- Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax AzacitidineStatus unknownNCT06263387
- Cladribine Venetoclax in Monocytic AMLActive, not recruitingNCT06232655Phase 2
- A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid LeukemiasActive, not recruitingNCT06226571Phase 1
- Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid LeukemiaCompletedNCT06211452Phase 3